NOVOCODEX
NovoCodex has been engaged in the business of genetic engineering, and cell culture, among others.
NOVOCODEX
Industry:
Clinical Trials Health Care Product Research
Founded:
2015-01-01
Status:
Active
Total Funding:
400 M CNY
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Nodexus
Nodexus is democratizing access to live single cells for applications including gene editing, drug development, and more.
Qihan Biotech
Qihan Biotech is a gene-editing organ transplantation technology developer.
Founder
Investors List
Matrix Partners China
Matrix Partners China investment in Series A - NovoCodex
Lilly Asia Ventures
Lilly Asia Ventures investment in Series A - NovoCodex
CMG-SDIC Capital Management
CMG-SDIC Capital Management investment in Series A - NovoCodex
More informations about "NovoCodex"
NovoCodex - Crunchbase Company Profile & Funding
NovoCodex is a biopharmaceuticals company that specalizes in the business of genetic engineering, and cell culture. NovoCodex is involved in the research, development, and …See details»
NovoCodex Biopharmaceuticals - PitchBook
Information on valuation, funding, cap tables, investors, and executives for NovoCodex Biopharmaceuticals. Use the PitchBook Platform to explore the full profile.See details»
Matrix,LAVco-lead$62mroundinChinesebiotechfirmNov…
NovoCodex Biopharmaceuticals, a subsidiary of Shanghai-listed pharmaceutical major Zhejiang Medicine, has raised 400 million yuan ($62 million) in its Series A round to expedite the development of antibody-drug conjugate (ADC).See details»
NovoCodex - Funding, Financials, Valuation & Investors
NovoCodex is a biopharmaceuticals company that specalizes in the business of genetic engineering, and cell culture.See details»
Novocodex Biopharmaceuticals Company Profile - Craft
It specializes in genetic engineering, cell culture, toxin synthesis, conjugation, formulation and filling, preclinical study, and clinical study. See insights on Novocodex Biopharmaceuticals …See details»
NovoCodex Biopharmaceuticals - Products, Competitors, …
NovoCodex Biopharmaceuticals is a company engaged in the research and development of biopharmaceuticals within the biotechnology sector. The company specializes in the …See details»
NovoCodex Biopharmaceuticals - VentureRadar
Offers genetic engineering, cell culture, toxin synthesis, ADC conjugation, preparation filling, and preclinical and clinical research services since 2017. "The company's innovative biologic drug …See details»
NovoCodex - Crunchbase
NovoCodex is a biopharmaceuticals company that specalizes in the business of genetic engineering, and cell culture.See details»
NovoCodex Biopharmaceuticals Co., Ltd. announced that it has …
Mar 18, 2021 · NovoCodex Biopharmaceuticals Co., Ltd. announced that it has received CNY 400 million in its series A round of funding co-led by Eli Lilly Investment Consulting Co., Ltd., and …See details»
Ambrx Announces Positive Data on ARX788 for the Treatment of …
Jun 30, 2021 · ACE-Gastric-01 is a Phase 1 clinical study of ARX788 for the treatment of HER2+ metastatic gastric/GEJ cancer that is being conducted in China by Ambrx’s partner, NovoCodex.See details»
Ambrx Announces NovoCodex’s Dosing of First Patient with …
Nov 9, 2022 · Building on the NovoCodex Phase 1 data, Ambrx plans to expedite its Phase 1a trial of ARX305 by starting at higher doses (i.e., doses closer to a recommended Phase 2 dose).See details»
Ambrx - Ambrx Biopharma Inc. Announces Strategic …
Ambrx highly values its global partners and plans to continue working collaboratively with NovoCodex (ARX788, ARX305), Sino Biopharm (ARX102) and BeiGene (research …See details»
Ambrx Announces NovoCodex's Dosing of First Patient with …
Nov 9, 2022 · Ambrx and NovoCodex initiate Phase 1 trial for ARX305, targeting CD70 in advanced tumors, signaling key milestone payments and strategic advancements.See details»
Series A - NovoCodex - 2021-03-19 - Crunchbase
Mar 19, 2021 · Novocodex raises USD 62M in funding round.See details»
Ambrx and NovoCodex form Second Collaboration to Develop …
Oct 23, 2019 · Under the agreement, Ambrx and NovoCodex will join forces to continue the development of ARX305, an Ambrx enabled ADC for the treatment of CD70 positive cancers.See details»
Ambrx and NovoCodex form Second Collaboration to Develop …
Oct 23, 2019 · Ambrx and NovoCodex Biopharmaceuticals Ltd., (NovoCodex), a majority owned company of Zhejiang Medicine Co Ltd., today announced that they have formed a second …See details»
Ambrx Announces NovoCodex’s Dosing of First Patient with …
Nov 9, 2022 · According to their development agreement, NovoCodex and Ambrx will collaborate in the development of ARX305 up until the completion of Phase 1 clinical trials.See details»
Ambrx Announces Encouraging Preliminary Safety and Efficacy …
Dec 9, 2022 · Two Phase 3 studies and one registration enabled Phase 2 study with ARX788 (ACE-Breast-02, ACE-Gastric-02, and ACE-Breast-08) conducted by Amrbrx’s partner, …See details»
Amidst Restructuring, Ambrx Doses First Patient with Anti-CD70 ADC
Nov 10, 2022 · The ADC, dubbed ARX305 and developed by the San Diego-based company, will be assessed in an early-stage trial by partner NovoCodex, a Chinese pharmaceutical …See details»
ARX-102 - Drug Targets, Indications, Patents - Synapse - Patsnap
As part of this strategic update, Ambrx will streamline its organization to improve efficiency and reprioritize its development pipeline to focus on oncology assets with the greatest potential …See details»